In the last three months, 4 analysts have published ratings on Conmed (NYSE:CNMD), offering a diverse range of perspectives from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $51.5, along with a high estimate of $55.00 and a low estimate of $47.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.94%.

Deciphering Analyst Ratings: An In-Depth Analysis

A comprehensive examination of how financial experts perceive Conmed is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Conmed's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Conmed analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Conmed: A Closer Look

Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.

Key Indicators: Conmed's Financial Health

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: Conmed displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 6.7%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 0.85%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Conmed's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.28%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Conmed's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.12% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.85.

Analyst Ratings: What Are They?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.